6 Oct 2023 , 03:34 PM
Sun Pharmaceutical Industries announces US FDA acceptance of deuruxolitinib new drug application for alopecia areata treatment. The investigational oral drug is intended for adults with moderate to severe alopecia areata.
Sun Pharma submits 8mg twice daily regimen of deuruxolitinib for USFDA review in the new drug application. The potential of deuruxolitinib as a crucial treatment option emphasized by Sun Pharma CEO for those dealing with chronic alopecia areata.
NDA for deuruxolitinib based on comprehensive Phase III trials involving 1,200+ patients across 135+ clinical trial sites. Recent data from these trials presented at major dermatology meetings, showcasing the drug’s potential effectiveness.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
